Incyte Announces Multiple Abstracts from its Dermatology Por

New data on ruxolitinib cream (Opzelura) in vitiligo and atopic dermatitis will be presented, including 52-week results from the Phase 3 TRuE-V vitiligo program which will be featured as a late-breaking

Related Keywords

Delaware , United States , Boston , Massachusetts , American , Erica Cech , Catalina Loveman , Christine Chiou , Jim Lee , Exchange Commission , American Academy Of Dermatology , Mental Health , Group Vice , American Academy , Annual Meeting , Group Vice President , Inflammation Autoimmunity , Week Phase , Breaking Research , Ruxolitinib Cream , Atopic Dermatitis , Anatomic Region , Pooled Analysis From Two Randomized Phase , Ev Phase , Pigmentary Disorders Vitiligo , Patient Demographics , Baseline Clinical Characteristics , Findings From , Term Safety , Disease Control , Ruxolitinib Cream Among Black , African American Patients With Atopic Dermatitis , Pooled Results From Two Phase , Cream Provided Progressive Improvement , Global Assessment Treatment Success , Natural History , Patients With Vitiligo , Healthcare Professionals Treating Them Recognize , Living With , European Marketing Authorization Application , New Drug Application , Incyte , Nnounces , Multiple , Abstracts , Rom , Ermatology , Portfolio , Wave , Teen , Accepted , Presentation , 022 , Academy , Nnual , Meeting ,